MedTrace Logo

"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "

NCT02419118 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-11-07

No results posted yet for this study

Summary

Daratumumab is a new treatment for patients with myeloma. While many patients benefit from this treatment some do not and the mechanism(s) of failure are poorly understood. This study aims to clarify aspects of resistance to treatment with daratumumab in order to improve patient outcomes in the future.

Conditions

Interventions

DRUG

Daratumumab

Treatment of myeloma patients with Daratumumab

DRUG

Lenalidomide

Treatment of myeloma patients

DRUG

Dexamethasone

Treatment of myeloma patients

Sponsors & Collaborators

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Torben Plesner, MD · Vejle Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-10-01
Completion
2015-10-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02419118 on ClinicalTrials.gov